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Hôpital Beaujon, Clichy, FranceSummary IntroductionHCV infection is a global health problem that affects 170 million
people worldwide. The severity of the disease varies from asymp-
tomatic chronic infection to cirrhosis and hepatocellular carci-
noma (HCC). Recently, the standard of care for genotype 1
patients has greatly improvedwith the addition of protease inhib-
itors (telaprevir or boceprevir) to pegylated interferon (PegIFN)
and ribavirin (RBV). The prediction of ﬁbrosis progression and
the response to antiviral treatment are two major issues in the
management of patients with chronic hepatitis C. Differential
expression of mRNAs was ﬁrst analyzed for both progression of
ﬁbrosis and treatment response. Speciﬁc polymorphisms, associ-
ated with either ﬁbrosis or viral response, were identiﬁed thanks
to major improvements in genome scanning technologies. Since
2009, several independent genome wide association studies
(GWAS) have reported an association between genetic polymor-
phisms within the IL-28B promoter and both natural and treat-
ment-induced clearance in genotype 1 infected patients. These
different studies showed the strong association and the impor-
tance of IL-28B polymorphisms in the treatment response.
Combining the different genetic factors could improve their
predictive value and help identify patients at a high risk of pro-
gression of ﬁbrosis as well as those with a lower chance of
responding to treatment. The aim of this review was to discuss
the genomic factors (mRNAs, miRNAs, and SNPs) and HCV infec-
tion with clinical implications for either progression of ﬁbrosis
or treatment response. Recent ﬁndings on the IL-28B polymor-
phism and its application in clinical practicewill also be discussed.
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the ﬁrst indication for liver transplantation in Europe and the
United States. The progression from early stage of ﬁbrosis to cir-
rhosis varies widely among patients with chronic hepatitis C.
Identifying patients in whom ﬁbrosis will progress rapidly
as well as non-responders is crucial for disease prognosis.
Some deﬁned markers such as male gender, age, alcohol, and
obesity may play a role in accelerating ﬁbrosis and treatment
failure. The current standard of care for HCV genotype 1
patients is triple therapy with the addition of protease inhibi-
tors (boceprevir and telaprevir) to pegylated interferon (Peg-
IFN) plus ribavirin (RBV). For genotype non-1 patients,
treatment is still PegIFN and RBV. The prediction of non-
response to treatment is mandatory to avoid side effects and
reduce costs.
Since the sequencing of the entire human genome in 2001,
major advances have been made in genotyping technologies, in
particular, the decrease in the cost of genotyping, the large-scale
discovery of single nucleotide polymorphisms (SNPs), the devel-
opment of massive multiplexed genotyping and the efforts of
SNPs consortiums and the HapMap project.
Since 2009, at least 4 different GWAS have investigated geno-
mic markers associated with a response to PegIFN/RBV in
patients with chronic HCV (CHC). The same SNPs located in the
promoter region of IL-28B were highly associated with natural
and treatment-induced viral clearance [1].
The aim of this review was to present and discuss the major
genomic markers that have been associated with either ﬁbrosis
progression or treatment response in patients with CHC. The12 vol. 57 j 1110–1125
iomarkers.
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 for prognosis of
chronic hepatitis C (CHC) and decision to treat. Liver
biopsy remains the gold standard to distinguish between
moderate and mild fibrosis.  Several genetic factors have
been  to help  diagnose  progression
• Genome wide association studies (GWAS) have
 previously unknown markers associated
with  progression and antiviral response. 
Some polymorphisms have been associated with viral
response and  progression, due to their ability to
modulate expression of genes whose products play a
role in the antiviral response or  progression
• The cirrhosis risk score (CRS) including a combination
of 7 SNPs may distinguish patients at high risk 
of developing cirrhosis. Several SNPs regulating
expression of MMP9 and MMP1 have been associated
with  and its progression. IL-28B is not associated
with  stage
• Fibrosis progression is different for each patient; some
patients are  as “rapid  and others as
“slow  The progression likely depends on the
intensity of aggressive stimuli (HCV, alcohol, etc.), the
duration of exposition to the agent, but also the host
genetics and the environment (obesity, etc.)
• Fibrosis regression is different for each patient. The
regression is directly associated with the control of the
aggressive agent (HCV eradication, control of alcohol
consomption, etc.), but also with the host genetics
(capacity of  degradation and repair), and the
environment. Some patients are  as “rapid
regressors” and some as “slow regressors” 
• By scanning several hundreds of thousands SNPs,
4 independent GWAS reported single nucleotide
polymorphisms (SNPs), near the IL-28B (IFNλ3) region,
that were associated with response to PegIFN/RBV
treatment in genotype 1 patients. The association of
IL-28B SNPs with viral response is less strong in HCV
genotypes 2 and 3 than in genotypes 1 and 4
• The molecular mechanisms of IL-28B SNPs are 
unknown
• Interferon stimulated genes (ISGs) are highly expressed
in the livers of non-responders at baseline compared
to sustained virological responders (SVR). ISG intra-
hepatic expression remains a better predictive factor of
antiviral response in patients with chronic hepatitis C
than the IL-28B genotype. However, IL-28B is non-
invasive and easier to perform
• The SNP rs12979860 CC is associated with both SVR
and RVR. RVR is a strong predictor of SVR whatever the
IL-28B genotype. In patients with RVR, rs12979860 CC
genotype is not associated with higher SVR rates
• IL-28B polymorphisms may be used in combination with
some ISGs, viral genotype and other SNPs to improve
prediction of treatment response. IL-28B SNP may be
less predictive in triple therapy and future combination
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Journal of Hepatology 2012combination of these different markers may help identify a
strong predictive genetic signature for ﬁbrosis progression and
treatment response.
Genome wide association studies, power and limitations
When the GWAS technology was ﬁrst described in 1996 [2]
(Box 1), its main limitations were due to the lack of technology
and the authors suggested geneticists to keep their samples for
future experiments. Originally, the HapMap project characterized
the pattern of genetic variations in 270 individuals of different
ethnicities. The dataset then amounted to a total of 3.1 million
SNPs, which is a very important resource for the selection of
genetic markers and genotyping assays.
GWAS involves identiﬁcation of statistical associations
between a trait or disease and a genetic polymorphism (SNP),
throughout the entire genome.
Linkage disequilibrium can be used to indirectly determine
untyped variations around an SNP. The r2 value, which is com-
monly used to evaluate linkage disequilibriums,measures the cor-
relation between alleles at a nearby genetic variant. If alleles of 2
SNPs are always found on the same chromosome, there is a perfect
correlation and r2 = 1. In practice, this means that typing one of
these 2 SNPswill provide complete allele information at the 2 sites.
If r2 <1 between the 2 alleles, the sample size will need to be
proportionally increased to detect a signiﬁcant association [3].
So far only SNPs with a frequency of more than 5% of the
minor allele can be detected effectively by linkage disequilibrium
in GWAS. Thus, the HapMAp project does not provide perfect cov-
erage of GWAS so that even in very large GWAS it is impossible to
detect rare low frequency genetic variants. However, the technol-
ogy will probably improve in the future, thus increasing coverage
of low frequency variants.
Different methods of correcting the p values of associations
have been described to counteract associations due to chance
because of the many statistical tests. The most commonly used
approach consists in the adjustment of the p value according to
Bonferroni. The threshold of 0.05 is divided by the number of SNPs
analyzed, which leads to an adjusted threshold of 106 to 108, for
current available assays. However, several real associations may
be lost by deleting all associations with a p value above this
threshold. Furthermore, to improve the statistical relevance of
GWAS, it is extremely important to replicate signiﬁcant associa-
tions in at least one independent cohort of individuals (trait and
control).
The GWAS technology has greatly improved in the last decade,
however, the detection of rare variants would probably improve
this approach even more [3].Fibrosis
Liver ﬁbrosis is deﬁned as the excess accumulation of extracellu-
lar matrix proteins. Fibrogenesis is a complex dynamic process,
mediated by necro-inﬂammation, and activation of stellate cells
[4]. Fibrosis progression determines the prognosis and thus the
need for treatment. It is therefore crucial to monitor ﬁbrosis in
patients with CHC. Several studies have assessed the identiﬁca-
tion of mRNAs and miRNAs expression during ﬁbrosis (Table 1)
and will be discussed in the ﬁrst part of the review.
The natural history of HCV and factors associated with ﬁbrosis
progression are discussed in Box 2.vol. 57 j 1110–1125 1111
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Box 1 
Principles of GWAS and its clinical and biological application
GWAS uses dense maps of SNPs covering the entire genome to look for allele frequency differences between cases (disease or trait) 
and controls.
The study of the association between the isolated marker and a disease or trait is based on the selection of genes that are already 
known to play a role in the trait, while GWAS is based on whole genome scanning. Thus, the main advantage of GWAS is to identify 
both genes that are expected to play a role and genes that are not, providing new insights into the understanding of the physiopathology 
of thousands of SNPs are tested in a single GWAS for their association with a disease or trait in hundreds or thousands of people. A 
The results obtained with GWAS can be used in two different ways: (i) to help to understand the physiopathology of the disease or trait 
tested and (ii) to improve personalized medicine. GWAS can identify markers that may be used to develop new therapeutic targets and 
be tested as new biomarkers to evaluate the risk in patients associated with this variant.
of the disease. This technique has revolutionized the identification of genetic markers associated with common disease or traits. Hundreds
significant difference in frequency suggests that the corresponding region of the genome encodes for functional DNA variants that may
influence the tested disease or trait.
ReviewVariation of mRNAs expression and ﬁbrosis
A deregulation of gene expression mainly affecting the IFN ab
and c pathways ( STAT1, STAT2, ISGF3G/IRF9, IFI27, G1P3, G1P2,
OAS2, MX1, CXCL9, CXCL10, CXCL11, and Viperin) has been
reported in patients with CHC and mild ﬁbrosis [5,6].
The transition from mild to moderate ﬁbrosis is crucial in the
decision to treat. The expression of 240 liver genes has been com-
pared in 62 patients with mild ﬁbrosis (F1) and moderate ﬁbrosis
(F2). Twenty-two genes were upregulated in F2 and mainly
involved the cytoskeleton, growth factor cytokines, growth factor
receptors, extra-cellular matrix remodeling, and the cell junction
[7].
Liver steatosis is frequent in patients with CHC [8]. Three
genes involved in the inﬂammatory pathway ( SITPEC, SIGIRR,
and TOLLIP) have been described as speciﬁcally associated with
advanced steatosis in CHC [9].
One study investigated changes in liver mRNAs expression in
13 transplanted patients comparing patients in whom ﬁbrosis
progressed with those in whom it did not, before and after
transplantation [10]. Fifteen of the 31 upregulated genes
encoded for markers of myoﬁbroblasts and myoﬁbroblast-like
cells. Liver stress injury and ﬁbrosis development can cause
an increase in myoﬁbroblasts due to activation of HSCs and
their conversion into the contractile phenotype [10]. It is inter-1112 Journal of Hepatology 2012esting to note that these data suggest that early ﬁbrosis pro-
gression may be associated with a reduction in the pools of
quiescent HSCs and with an increase in the number of myoﬁ-
broblast-like cells.
Variation in micro-RNAs expression and ﬁbrosis
Micro-RNAs regulate up to 60% of cellular mRNA expression and
stability [11–14].
In one study, mir-21 expression was found to be correlated to
both HCV viral load and ﬁbrosis [15]. Results are conﬂicting for
mir-122 but it is probably only weakly or not associated with
viral load [15,16]. Two studies have reported a correlation
between mir-122 expression, liver damage, and stages of ﬁbrosis
[15,16] while another did not ﬁnd any association with mir-122
expression in the serum of patients with CHC [17].
A recent study demonstrated that the different members of
the mir-29 family were all downregulated in HCV infected
patients. Moreover, freshly isolated HSCs expressed a high rate
of mir-29, which was rapidly and markedly reduced after HSC
activation [18]. Mir-29 targeted various types of collagen and,
interestingly, mir-29 inhibition in mice has been shown to upreg-
ulate collagen expression in the liver [19]. Thus, mir-29 downreg-
ulation during HSCs activation might play a role in ﬁbrosis by
inducing direct accumulation of collagen in the liver.vol. 57 j 1110–1125
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Box 2 
between parenchymal cells (hepatocytes) and sinusoidal endothelial cells of the hepatic lobule. HSCs are quiescent and store vitamin 
A and retinyl palmitate in lipid droplets within the cytoplasm. Under physiological conditions, HSCs regulate vitamin A homeostasis by 
expressing specific receptors for retinol-binding protein (RBP) at the cell surface. Activation of retinol is regulated by endocytosis of the 
complex retinol/RBP. HSCs are activated by different stimuli such as chronic viral infection or alcohol intake. Activated HSCs proliferate 
matrix protein, including collagen, proteoglycan and adhesive glycoproteins, and release vitamin A. 
Kupffer cells are the resident liver macrophages in the liver. They remove material from the portal circulation. Kupffer cells direct the 
destruction of hepatocytes by producing harmful soluble mediators and act as antigen-presenting cells during viral infections. Kupffer 
T cells. They are one of the main 
sources of transforming growth factor 
When hepatocytes undergo necrosis from different stimuli, infiltrating lymphocytes surround the parenchyma.
1 production, which induces the transformation of HSCs into myofibroblasts.
cells produce a significant amount of chemoattractant molecules for cytotoxic CD8 and regulatory
and undergo a proliferative myofibroblast (MF) phenotype. Under pathological conditions, HSCs produce large amounts of extracellular
The accumulation of extracellular matrix proteins and marked modifications in liver architecture define fibrosis progression. In the
normal liver, hepatocytes form parenchyma. Hepatic stellate cells (HSCs), that are key cells involved in fibrogenesis, are located
β
JOURNAL OF HEPATOLOGYSingle nucleotide polymorphisms and ﬁbrosis
Identiﬁcation of SNPs that modulate gene expression associated with
ﬁbrosis and ﬁbrosis progression
Several studies have tried to indentify SNPs associated with
either ﬁbrosis progression or treatment response (Table 2).
Matrix metalloproteinases (MMPs) play an important role in
ﬁbrosis progression. MMP-1, MMP-3, and MMP-9 gene polymor-
phisms have been shown to inﬂuence the transcriptional activity
of their respective gene promoters. Interestingly, both MMP-1 2GJournal of Hepatology 2012homozygote and MMP-9 C allele were more frequent in HCV
patients with cirrhosis than in those without cirrhosis [20].
Monocyte chemotactic protein 1 (MCP-1) is upregulated in
HSCs during CHC. MCP-1 harbors a functional polymorphism
located in its promoter. Interestingly, the 2A homozygote geno-
type in this speciﬁc polymorphism was more frequent in patients
with mild ﬁbrosis [21].
Decreased vitamin D levels and genetic variations in the vita-
min D receptor (VDR) gene have been described as an important
modulator of multiple diseases, including hepatic disorders [22].vol. 57 j 1110–1125 1113
Table 1. Variations in mRNAs and miRNAs expression associated with ﬁbrosis progression. (A) Markers identiﬁed by candidate gene strategy; (B) markers identiﬁed by
scanning approach.
A References Patients (n) Targets (n) Results
mRNAs 
Asselah et al., [7] 62 240 cytoskeleton (KRT19 and SCG10) 
growth factors cytokines (CXCL6, IL-8, IL-2, IL-1A and 
CXCL10) 
growth factors receptors (CCR2, CXCR3 and CXCR4) 
extra-cellular matrix remodelling (TIMP1, MMP7 and MMP9) 
cell junction (ITGA2 and CLDN4)
miRNAs 
Marquez et al., [15] 20 2 mir-122, mir-21
Morita et al., [16| 185 1 mir-122
Bihrer et al., [17] 68 + 19 1 mir-122
B References Patients (n) Targets (n) Results
mRNAs
Smith et al., [10] 13 (0, 3, 6 and 
12 months 
after liver 
transplantation)
13,026 MF) and MF like cells (CARP, 
MAGP2, NDRG4, COL12A1, MYOM1, CHRND, FHL1, 
MYBPC1, CASQ2, CHRNA1, AMPD1, CACNA1S, MYH2, 
MYL2 and NEB) 
retinoid related proteins (RARRES3, STRA13, RXRB, RXRA, 
RDH5, RBP4, RBP5, RODH and RODH-4) 
ApoE
inflammatory pathway (
markers of myofibroblasts (
Chiappini et al., [9] 43 22,300 SITPEC, SIGIRR and TOLLIP)
miRNAs
Bandyopadhyay et al., [18] 22 + 4 346 mir-29 family 
Table 2. Identiﬁcation of SNPs associated with ﬁbrosis and the response to antivirals in patients with chronic hepatitis C.
Genes Description of polymorphisms 
SNP have an identified role in fibrosis
AA homozygote at position -2518 is more frequent in mild fibrosis
Fi
br
os
is
MMP1 and 9 MMP1 2 G homozygote at position -1607 and MMP9 C allele at position -1562 are more frequent in cir-
rhotic patients
CCL2 (MCP1) 
Cirrhosis risk score 7 SNPs (AZIN1: rs62522600; TLR4: rs4986791; 
: rs2878771) have been all associated with fibrosis.
that modifies the fibrogenic potential of HSCs
TRPM5: rs886277; AP3S2: rs2290351; B008027: 
rs4290029; STXBP5: rs17740066; AQP2 AZIN1 SNP 
generates an alternative spliced from of 
The rs738409 mutant GG is associated with higher risk of steatosis, fibrosis and fibrosis progression
Haplotype rs1544410 C, rs7975232 A and rs731236 A with fibrosis progression and cirrhosis
AZIN1
TLR4
PNPLA3 
Vitamin D receptor 
(VDR)
Vi
ra
l r
es
po
ns
e
KIR/HLA The combination of KIR2DL3 and HLAC1 is more frequent in patients with high SVR rates
IL6 The SNP rs1800795 CC is associated with low IL6 production and high SVR rates
IL10 Mutations at positions -819, -1082 and -592 are associated with modulation of IL-10 expression and differ-
ent viral SVR rates
IFNG The mutation C764G is associated with higher SVR rates
CCR5 CCR5Δ32 deletion is associated with resistance to HIV-1 and with poor SVR rates in HCV patients
IL28B rs1299860 CC genotype and rs8009917 TT are both associated with high SVR rates
ReviewVDR genotyping in 251 patients with chronic hepatitis C showed
an association between the haplotype rs1544410 C, rs7975232 A,
and rs731236 A with ﬁbrosis progression and cirrhosis. Forty-ﬁve
percent of the [CCA]-haplotype patients had rapid ﬁbrosis pro-
gression and 21.1% had cirrhosis [23].1114 Journal of Hepatology 2012Cirrhosis risk score
A gene-centric disease association study of 24, 832 putative func-
tional SNPs was performed to assess the association of SNPs with
cirrhosis in a cohort of 433 patients with CHC [24]. One SNP
located in the DEAD box polypeptide 5 was associated with anvol. 57 j 1110–1125
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increased risk of advanced ﬁbrosis while the second SNP, located
in the gene encoding carnitine palmitoyltransferase 1A (CPTA1),
was associated with a decreased risk of advanced ﬁbrosis [24].
In a second study, the authors conﬁrmed all signiﬁcant SNPs,
and selected 361 markers to build a signature predicting cirrho-
sis, called the cirrhosis risk score (CRS) [25]. Interestingly, DDX5
and CPT1A were not selected for the ﬁnal 7 SNPs for the CRS. Pos-
sible reasons were (i) lower odds ratios and frequencies in the
risk group and (ii) decreased robustness and accuracy of these
2 SNPs in multivariate analysis compared to the 7 selected genes.
Of the 7 CRS genes, antizyme-inhibitor-1 (AZIN1) and Toll-like
receptor 4 (TLR4) have been shown to play a role in ﬁbrosis. A
recent study has reported that the association of AZIN1 SNP with
the rapid progression of ﬁbrosis, leads to enhanced generation of
a novel alternative splice form from AZIN1 that modiﬁes the ﬁbr-
ogenic potential of HSCs [26]. All 7 SNPs were associated with the
risk of cirrhosis with odds ratios ranging from 1.86 to 3.23. How-
ever, the AUC of each SNP was <0.6, showing that predictability
was moderate when they were used individually [25]. The
addition of clinical factors to the group of SNPs or each of them
individually did not signiﬁcantly improve the AUC.
Two major limitations are associated with the use of CRS to
identify patients with rapid progression of ﬁbrosis: (i) CRS cut-
off values may only distinguish patients with a very high risk of
cirrhosis (ii) CRS was identiﬁed in Caucasian patients so it may
not be applicable to all ethnic groups [25].
In another study, paired liver biopsies from 271 untreated
patients with CHC (F0 = 104, F1 = 101, and F2 = 59) were fol-
lowed-up for at least 60 months. Mean CRS was signiﬁcantly
higher is patients in whom ﬁbrosis progressed, especially in
patients with F0 at the initial biopsy [27].
CRS remained the only variable associated with ﬁbrosis pro-
gression in multivariate analysis, including gender and alcohol
intake [28].
Genetic studies have reported an association between
advanced steatosis and speciﬁc SNPs located in genes encoding
microsomal triglyceride transfer protein (MTP G493T) [29–31],
peroxisome proliferator activated alpha (PPAR L162V) [32],
methylenetetrahydrofolate reductase (MTHFR C677T) [33,34],
cytokines playing a role in the inﬂammatory response such as
interlekin-10 and -6 (IL-10 and IL-6) [35], transforming growth
factor beta-1 (TGFB1) [35], tumor necrosis factor (TNF, 238
position) [36,37] and leptin receptor (LEPR) [35].PNPLA3 and ﬁbrosis
A non-synonymous sequence variation (rs738409 C/G) encoding
an isoleucine to methionine substitution in the adiponutrin/pat-
atin-like phospholipase-3 (PNPLA3) has been shown to be
strongly associated with increased hepatic fat levels [38]. This
SNP was then shown to be associated with disease severity, ﬁbro-
sis, and steatosis in non-alcoholic fatty liver disease (NAFLD)
[39,40] and in alcoholic liver disease (ALD). Moreover, the same
SNP was also associated with elevated liver enzymes in healthy
subjects [41]. Interestingly, patients with CHC carrying the
rs738409 mutant GG allele had a high risk of steatosis as well
as ﬁbrosis and ﬁbrosis progression [42–44]. However, there are
conﬂicting results reporting that PNPLA3 rs738409 GG mutant
variant may be a prominent risk factor for HCC in patients with
alcoholic cirrhosis, while its effects were negligible in patients
with HCV cirrhosis [45].Journal of Hepatology 2012IL-28B and ﬁbrosis
The analysis of rs8099917 SNPs during liver ﬁbrosis in chronic
hepatitis C showed that the G allele, previously shown to be a risk
of treatment failure, was associated with lower activity and less
ﬁbrosis with a trend towards a lower rate of ﬁbrosis progression.
Interestingly, when patients were stratiﬁed according to HCV
genotype, the association was more signiﬁcant in HCV genotype
non-1 infected patients [46]. However, independent studies have
reported that ﬁbrosis progression was not associated with either
rs12979860 or with rs8099917 [47,48].
The analysis of a larger cohort showed that PNPLA3 polymor-
phisms were strongly associated with an increased risk of steato-
sis in patients with HCV (excluding genotype 3) while the
association with IL-28B SNPs was weak [49]. Steatosis was found
in 22.5% and 39.6% of two independent cohorts of patients carry-
ing the favorable IL-28B genotype vs. 47.6% and 67.4% of IL-28B
non-favorable genotypes, respectively [50].
It has been suggested that levels of LDL cholesterol are signif-
icantly higher in CHC subjects carrying the rs12979860 CC geno-
type compared to CT and TT [51]. However, triglyceride levels
were lower in patients carrying the IL-28B CC genotype. IL-28B
CC may be associated with less pronounced lipid metabolism dis-
turbances, as shown by serum lipoprotein levels and hepatic
steatosis.
Altogether, the different studies have suggested that various
SNPs, especially, AZIN1 and PNLPA3 are associated with ﬁbrosis
progression. Moreover, several extra-cellular-matrix and chemo-
kine mRNAs are probably upregulated in patients with more
advanced ﬁbrosis. However, it is important to bear in mind that
some studies have investigated ﬁbrosis progression by analyzing
paired biopsies while other studies were cross-sectional. Taking
into account the duration of infection could provide useful infor-
mation to improve the evaluation of ﬁbrosis progression in cross-
sectional liver biopsies.Prediction of treatment response
The current standard of care for chronic hepatitis C and the fac-
tors associated with a non-response are shown in Box 3.
Variation in mRNAs expression and treatment response
An 8-gene subset accurately predicted treatment response (GIP2/
IFI15/ISG15, ATF5, IFIT1, MX1, USP18/UBP43, DUSP1, CEB1, and
RPS28) using a number of independent classiﬁer analyses [52].
Interestingly, another study evaluated the expression proﬁle of
a selection of genes in SVRs and NRs. IFI27 and CXLC9, a two-gene
signature, predicted the response to treatment in 79% of the
patients with a predictive accuracy of 100% for NRs and 70% for
SVRs [53]. One study showed that SVR could be predicted, prior
to treatment, by analyzing gene expression of signal transducer
and activator of transcription-6 (STAT-6) and suppressor of cyto-
kine signaling-1. Interestingly, even after 24 h of treatment, IFN-
dependent gene expression can help predict the probability of
achieving an SVR [54]. Many of the genes, found to be upregu-
lated in non-responders and responders, encode molecules
secreted in the serum (cytokines) [55,56]. Thus, they are a logical
approach to the development of serum markers to predict treat-
ment response.vol. 57 j 1110–1125 1115
Box 3 
Current treatment in chronic hepatitis C and predictive 
factors of non-response 
Treatment for genotype non-1 patients, includes the 
combination of PegIFN/RBV [140-142]. In patients with 
genotype 1, the new standard of care includes the addition 
of a protease inhibitor (boceprevir or telaprevir) to PegIFN/
RBV. The goal of treatment is to obtain a sustained virological 
after 24 weeks of post-treatment follow-up. SVR results in 
the eradication of HCV infection and improvement of the 
histological outcome [143].
response (SVR) defined as undetectable HCV RNA in serum
Brief description of factors associated with SVR
Responsiveness to antiviral therapy depends upon viral 
factors as well as host factors. Viral factors associated with 
response to treatment are genotype and viral load [144]. 
rapid virological response, definedPatients who develop a 
as HCV RNA negative at treatment week 4 have a greater 
chance to achieve SVR (higher than 85%). Patients who 
do not have any decrease in viral load will not respond to 
treatment.
Advanced age, male gender, African American ethnicity, poor 
adherence, cirrhosis, insulin resistance (and also steatosis, 
diabetes and alcohol consumption) are all events associated 
with a poor response to PegIFN/RBV treatment [8, 145]. 
patients with immune depression, transplantation, or HIV co-
The chance of achieving an SVR significantly decreases in
infection [146].
Host factors Viral factors Treatment
Advanced age Viral load Regimen
Male gender Genotype Dose and duration
Ethnicity Quasispecies Side effects
Compliance
Insulin-resistance
Alcohol
Cirrhosis
Genetic
ReviewVariation of micro-RNAs expression and treatment response
Since cellular miRNAs regulate many cellular pathways, includ-
ing the immune response, some miRNAs are probably involved
in the modulation of antiviral response to PegIFN/RBV in CHC.
IFNb has been shown to rapidly modulate the expression of
numerous miRNAs, and 8 cellular IFNb-induced miRNAs have
sequence-predicted targets within the HCV genome [57].
The level of expression of intra-hepatic mir-122 has been
shown to be associated with HCV treatment response. Expression
of mir-122 was signiﬁcantly lower in primary non-responders
compared to early responders [58]. Interestingly, the anti mir-
122 (SPC3649 or miravirsen) molecules that inhibit HCV replica-
tion in chimpanzees [59] have recently been tested in a random-
ized double-blind study in treatment naïve patients with
genotype 1 [60].
However, an independent study investigating the expression
proﬁle of 470 cellular miRNAs in 99 CHCs, showed no signiﬁcant1116 Journal of Hepatology 2012difference in mir-122 expression between responders and non-
responders [61]. Eight miRNAs (mir-34b, mir-145, mir-143,
mir-652, mir-18a, mir-27b, mir-422b, and mir-378) were differ-
entially expressed in responders and non-responders. Moreover,
mir-34b and mir-422 were consistently and signiﬁcantly high
and low in non-responders both 12 and 24 weeks after the end
of the treatment [61].
Single nucleotide polymorphisms and treatment response
The main SNPs associated with SVR are summarized in Table 2.
Killer cell immunoglobulin-like receptors (KIR) activating and
inhibiting receptors
Natural killer (NKs) cells are a subset of lymphocytes that interact
directly with virus-infected cells, activate dentritic cells and
secrete Th1-type cytokines to increase antiviral cytotoxic T cell
response. NK responses are controlled by multiple activating
and inhibitory signals such as the KIR receptors. The ligands for
these receptors are human leukocyte antigen (HLA) class I. The
wide genetic diversity of the KIR family and the HLA class I gen-
erate a large number of combinations between KIR and HLA.
The combination of KIR2DL3 and HLA-C1 was associated with
both spontaneous clearance [62] and SVR [63,64] in patients with
CHC. This speciﬁc combination is supposed to have a weaker
inhibitory effect than other combinations leading to a stronger
NK cell response.
KIRs are clonally expressed on NKs in a stochastic manner.
Interestingly, Khakoo et al. reported a linear trend between the
number of KIR2DL3-HLA-C1 interactions and the ORs resolving
the infection. In this model, NK cell activity may be mediated
through weak inhibitory KIR2DL3-HLA-C1 interactions.
HLA class II alleles have been shown to play a role in spon-
taneous clearance in patients with HCV infection [65]. Interest-
ingly, a new interaction between KIR2DL3 and HLA class II
DRB1⁄1201 was found to be associated with spontaneous clear-
ance [66].
Prediction of treatment failure improved from 66% with
IL-28B to 80% using both IL-28B and HLA-C2/HLA-C2 genes
[67]. Moreover, the incorporation of two KIRs in a model
including viral load and ethnicity (SVR score) provided com-
plementary results with IL-28B across the CC, CT, and TT geno-
types [68].Genetic variants in the cytokine system and treatment response
STAT3 is mainly activated in the liver by IL-6, a cytokine that
has been involved in a variety of cell functions including stim-
ulation of hepatocytes to produce acute-phase proteins. The
polymorphism rs1800795 within the IL-6 promoter is associ-
ated with lower IL-6 levels compared to patients carrying the
G allele. Interestingly, higher response rates were reported in
patients carrying the rs1800795 G allele compared to C [69].
Yee et al. conﬁrmed the importance of rs1800795 in the viral
response and reported that several haplotypes containing
rs1800797, rs1800796, rs1800795, and rs2069830 within IL-6,
were associated with lower SVR rates [70]. IL-10 is a T-helper
type 2 cytokine that plays a major role in T and B cell regula-
tion. Peripheral blood mononuclear cells (PBMCs) from patients
with CHC had increased IL-10 mRNA and protein expression.
Moreover IL-10 has been shown to inhibit the production of
IFNa by stimulation with viral infections [71]. SNPs withinvol. 57 j 1110–1125
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Fig. 1. Frequency of IL-28B rs12979860 protective allele in worldwide
populations. rs12979860 CC is present in up to 80% of patients with Asian
ancestry and only 40% of patients with African ancestry. Figure adapted from data
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the IL-10 promoter at positions 819 and 592 have been
associated with different IL-10 levels. Interestingly, a strong
relationship was found between IL-10 polymorphisms and
response to IFNa treatment [72]. The frequency of 1082 GG
genotypes (high IL-10) was higher in patients who did not
eliminate the virus compared to controls. The higher level of
IL-10 in these patients was associated with a higher risk of
ineffective viral clearance and development of chronic infection
in female patients [73]. Of all the 8 SNPs identiﬁed in the
entire IFNc gene, the variant C764G was signiﬁcantly associated
with SVR. Functional analyses showed that the G allele con-
ferred higher promoter activity and a stronger binding afﬁnity
for HSF1 [74].reported in Thomas et al. [77].IL-28B and treatment response
Since 2009, several independent GWAS have reported a strong
association between SNPs, located in the IL-28B promoter region
with both natural and treatment-induced viral clearance (sum-
marized in Box 4).
Almost 85% of the patients with East Asian ancestry harbor
the C allele while only 40% of the patients with African-Ameri-
can ancestry carry genotype CC (Fig. 1) [75]. Thus, rs12979860
genotype diversity could explain the higher SVR rate in Asian
patients.
Interestingly, the rs12979860 CC genotype was also associ-
ated with early improved viral kinetics, a higher rate of rapid
virological response, and complete early virological response
[76]. The association of rs12979860 with viral response has been
conﬁrmed in independent cohort studies [77,78]. Interestingly,
IL-28B genotype was associated with treatment response in
patients with CHC but not in those with acute hepatitis C [79].
Moreover, jaundice was more common in CC patients (64%) dur-
ing acute infection than in CT (24%) or TT (6%). However, jaundice
was only associated with an increased chance of spontaneous
viral clearance in non-CC patients [80].
It has been suggested that the inﬂuence of rs12979860 geno-
type is a stronger predictive factor of SVR in patients with HCV-
G1 than in HCV non-G1 patients [81].
HCV-G-2 and G-3 patients carrying the rs12979860 CC allele
had a more rapid reduction in plasma HCV RNA, 3 days after
beginning of treatment. However, in accordance with previous
results [82], no signiﬁcant association was found between
rs12979860 and SVR in this cohort (98 genotype 2 and 241 geno-
type 3 patients). Interestingly, the assessment of IL-28B SNPs in
patients with genotype 2 or 3 might help determine the suitable
treatment duration [83].
In a recent study including 164 HCV genotype 4 patients
from different ethnic groups, IL-28B rs12979860 CC was associ-
ated with a better treatment response rate (81.8% vs. 46.5% and
29.4% for CC, CT and TT respectively). No signiﬁcant relation-
ship was found between rs12979860 and the stage of ﬁbrosis
[47].
Interestingly, it has been suggested that IL-28B SNP inﬂuences
HCV re-infection in patients receiving liver transplants.
Rs12979860 CC donors were associated with rapid, complete
early, and sustained virological response to PegIFN/RBV, com-
pared to CT and TT [84]. While the rs8099917 favorable genotype
was associated with a higher SVR rate in both recipients and
donors, recipient rs12979860 status will probably have a weaker
impact on viral response [84]. The use of both IL-28B genotype inJournal of Hepatology 2012donors and recipients and HCV core substitution predicted an
SVR with 83% sensitivity and 82% speciﬁcity [85].
Which speciﬁc IL-28B SNPs for the prediction of SVR?
Rs8099917 was identiﬁed in part by Rauch et al. and Tanaka
because rs12979860 was not investigated, since this SNP is
not present on either the Illumina Array or the Affymetrix
6.0 genotyping platform. Prediction of SVR with rs12979860
or rs8099917 will probably not matter in Caucasian patients.
However, the frequency of these SNPs in other ethnicities
may limit its use as predictive factor in the general population.
For example, the use of IL-28B in the decision to treat patients
with African ancestry, in which the frequency of the rs
12979860 favorable allele is only 40%, would exclude a large
number of patients from being eligible for treatment. There-
fore, IL-28B may be useful in combination with other predictive
factors to avoid excluding patients based on ethnicity.
CCR5 and HCV spontaneous viral clearance
The chemokine receptor CCR5 is activated through the binding of
RANTES. CCR5 is also a co-receptor of HIV-1. Interestingly, a com-
mon 32-base deletion in the CCR5 gene has been associated with
resistance to HIV-1 infection [86–88]. The potential role of CCR5
deletion in resistance to HCV has been studied and suggested
to adversely affect outcome of HCV infection [89–94]. However,
the different reports are conﬂicting.
A recent study has investigated the association of both
CCR5D32 and rs12979860 with spontaneous HCV clearance
[95]. The authors described an association of response rates with
rs12979860 CC only in CCR5 WT homozygous while HCV clear-
ance remained poor in CCR5D32 carriers even in CC patients.
Because the frequency of the CCR5D32 homozygous deletion is
rare, it is difﬁcult to study the inﬂuence of this mutation, either
alone or in combination with IL-28B genotype, on the outcome
of HCV infection. RANTES is expressed and secreted by HSCs
and induces migration, proliferation, and ﬁbrogenic properties
[96]. Different studies have reported the overexpression of
CCR5/RANTES in models of liver ﬁbrosis and in patients with
CHC [97]. Pharmaceutical companies have developed RANTES
inhibitors/CCR5 antagonists which have been successfully tested
in phase III studies in patients with HIV infection [98]. Interest-
ingly, the administration of the RANTES inhibitor greatly
improved liver ﬁbrosis in mice and accelerated ﬁbrosis regression
[99].vol. 57 j 1110–1125 1117
Box 4 
IL-28B 
IL-28B that are associated 
with HCV clearance [75, 82, 124, 125, 147].
A GWAS reported, for the first time, an association of response to PegIFN/RBV with
Since 2009, several independent GWAS have identified the same SNPs located in the promoter region of
IL-28B polymorphisms in patients with CHC.1137 
patients were included in the cohort. In the different SNPs scanned, rs12979860 was strongly associated with treatment-induced viral 
clearance in both European-American, African-American and Hispanics. In patients with European-American ancestry, the SVR rate 
reached almost 80% in patients with genotype CC. However, in African-American patients only 50-55% of patients with the C allele 
achieve an SVR [75]. 
Two SNPs (rs12980275 and rs8099917) were found to be significantly associated with viral response to PegIFN/RBV, in an
independent GWAS including 154 HCV genotype 1 Japanese patients. It is interesting to note that individuals who are homozygous for 
the rs8099917 minor allele GG (also called risk allele) were only found in NR [125]. 
rs8099917 SNP was strongly associated with treatment response in 2 groups of patients. The rs8099917 G allele could predict the 
response to treatment with 57% sensitivity and 67% sensitivity [124]. The authors showed that IL-28B had a distinct haplotype block and 
rs12980275, rs8105790, rs8103142, rs10853727, rs8109886 and rs8099917) associated with viral response. Indeed, this haplotype was
present in 31.5% of non-responders compared to 18.8% of responders [124]. 
there was no significant association in SNPs outside this block. The haplotype analysis identified a six-allele haplotype (GCCTAG:
In another GWAS, the rs8099917 TT genotype was associated with progression to chronic HCV infection in both mono-infected patients 
and HIV co-infected patients [82]. 
GWAS
identification by GWAS
IL-28B SNP Wild type/risk 
alleleidentified
Total 
population
% of 
SVR
Population 
studied 
% risk allele 
(within each ethnicity)
Viral 
genotype
Ge et al. rs12979860 C/T 1137 C/C: 79
C/T: 38
T/T: 26
American Caucasian
African American 
Hispanic
30
60
40
1
Tanaka et al. rs8099917 
rs12980275
T/G
A/G
314 T/T: 64
T/G: 13 
G/G: 0
Japanese 15
12
1
Suppiah et al. rs8099917 T/G 848 T/T: 56
T/G: 36
G/G: 31
Australian Caucasian 27 1
Rauch et al. rs8099917 T/G 914 T/T: 76
T/G: 22
G/G: 1
Swiss 17 1, 2, 3 
and 4
ReviewCombination of the IL-28B genotype with other factors to predict
treatment response
Host factors
High ISGs expression before treatment has been associated with a
low SVR rate [52,100]. Since treatment is based on PegIFN intake,
patientswho already have high ISG expressionmay not be as stim-
ulated as patients with low ISGs expression. Analysis of post-
treatment biopsies in patients with an RVR revealed that PegIFN
did not induce ISGs expression above pretreatment levels [100].
Both IFNa and k induce ISGs expression in HCV infected cells,
in vitro [101]. However, the kinetics of IFNk-mediated STAT acti-
vation and induction of effector genes were different from those
of IFNa, suggesting distinct mechanisms of IFNk- and IFNa-
induced antiviral states.
Intra-hepatic ISGs expression may be a better predictor of SVR
than IL-28B genotype [102,103]. Interestingly, global expression
of ISGs is strongly associated with genetic variation of IL-28B
[103]. Multivariate analysis of predictors of response showed that
a set of 4 ISGs were better predictors than rs12979860 SNP [102].
Despite a small sample size, another study reported an associa-
tion between rs12979860 SNP and 3 ISGs ( ISG15, IFI27, and
IFI6) [104]. Moreover, it has been suggested that IL-28B genotype
is associated with a speciﬁc cell-type modulation of ISGs expres-1118 Journal of Hepatology 2012sion ( MxA, PKR, OAS1, and ISG15) in hepatic cells and PBMCs
[105].
Several studies have shown that elevated IP10 levels may be a
prognostic marker of HCV treatment outcome in HCV genotype 1
infection [55,106–110]. The combination of serum IP-10 and
rs12979860 signiﬁcantly improved the prediction of SVR [111–
113]. Serum IP-10 was particularly informative in rs12979860
CT carriers, in whom high serum IP-10 levels resulted in a 64%
SVR compared to 24% in patients with low IP-10 [112]. Serum
IP-10 levels below 150 pg/ml signiﬁcantly predicted a greater
reduction of HCV RNA and increased SVR rates in genotype 1
rs12979860 CC patients [111].
It has been suggested that mir-122 expression is associated
with treatment outcome [58]. IL-28B genotype and mir-122
hepatic expression have been reported to be independently asso-
ciated with viral response [102].
Vitamin D deﬁciency is common in patients with chronic liver
disease. A recent study showed that vitamin D serum levels
improve prediction of an SVR in association with the IL-28B
rs12979860 polymorphism [114]. Vitamin D may be a key regula-
tor of the innate immune response [115]. However, this study was
retrospective. Furthermore, it has not been shown if correcting a
vitamin D deﬁciency before starting treatment may increase SVR
rates.vol. 57 j 1110–1125
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Fig. 2. SVR in triple therapy according to IL-28B rs12979860. Telaprevir-based
therapy improved both RVR and SVR across the different rs12979860 genotypes.
In patients with the unfavorable allele, the addition of telaprevir doubled SVR
rates. From 87% to 90% of the CC patients achieved an SVR with telaprevir
compared to 64% with PegIFN/RBV [135]. Therefore, patients with all different
rs12979860 genotypes beneﬁt from telaprevir triple therapy. Among patients
carrying the rs12979860 CC allele, 89% of treatment-naïve, and 82% of patients
with a treatment-failure had an early response (HCV RNA undetectable at week 8)
with boceprevir in addition to PegIFN/RBV. It is interesting to note that these
early responder patients were eligible for shorter treatment [139]. Naïve
genotype 1 patients with the favorable rs12979860 CC allele do not beneﬁt
(SVR) from boceprevir triple therapy compared to PegIFN/RBV.
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Viral factors and treatment response
Two amino acids substitutions at positions 70 and 91 within the
core protein and an accumulation of mutations in the interferon
sensitivity determining region (ISDR) located in the NS5A coding
region have been associated with viral response [116,117].
Interestingly, two studies [118,119] have shown that IL-28B
polymorphisms as well as amino acid 70 substitution in the core
protein were independently associated with SVR. The SVR rate in
patients receiving telaprevir in combination with PegIFN/RBV,
was high in those carrying the rs8099917 TT genotype whatever
the core 70 substitutions [118].
Of all the host and viral factors achieving an RVR is probably
the strongest predictor of SVR [120]. Early viral kinetics were
improved and there was a greater probability of achieving an
RVR with the rs12979860 CC genotype compared to CT and TT
[76,121]. RVR was a strong predictor of SVR whatever the IL-28B,
suggesting that achieving an RVR may compensate for the nega-
tive inﬂuence of IL-28B genotype. The CC IL-28B genotype was
associatedwith high SVR rates in non-RVR patients [76]. However,
in patientswith an RVR the rate of SVRwas high and therewere no
associations between IL-28B genotype and SVR [121]. It is not clear
whether the C allele is associated with a higher SVR rate in HCV
genotype 2 or 3 patients achieving an RVR [122,123].
IL-28B polymorphisms may be used in combination with sev-
eral factors; ISGs, viral genotype and other SNPs before, but also
during treatment, to improve prediction of treatment response.
The activity of IFNk and IL-28B polymorphisms
The activities of IFNks are summarized in Box 5.
Although multiple SNPs located in the IL-28B promoter region
have been identiﬁed and associated with SVR, none of them were
causal variants. The results of studies assessing variations of cir-
culating IFNks in the different IL-28B SNPs are contradictory
[104,119,124–126].
The putative causal SNP rs8103142 (Lys70Arg) within the IL-
28B coding region was identiﬁed in strong linkage disequilibrium
with rs12979860. However, there was no signiﬁcant difference
from the Lys70Arg mutation on either IL-28B activity or expres-
sion [104].
Detailedgenotypingwasperformedon the IL-28B coding region
in a cohort of 389 HIV/HCV co-infected patients. Homozygotes for
the haplotypes rs4803219, rs28416813, rs8103142, and
rs4803217 were strongly linked to the rs12979860 CC genotype
(r2 = 0.97). This speciﬁc haplotype was especially frequent in indi-
viduals with spontaneous clearance compared to those with CHC
[127], suggesting a possible effect of these SNPs on viral clearance.
Interestingly, IFNks were highly activated in chimpanzees
immediately after HCV infection while IFNabs were slightly
induced [128].
However, it is important to remember that while a common
variant associated with a disease in a GWAS is generally linked
to a causal effect that is nearby, this is not necessary the case.
Thus rs12979860 may be in strong linkage disequilibrium with
an unidentiﬁed causal SNP located in another gene.
IL-28B and future therapies
IFNk-based treatment
The strong association between IL-28B genotype and treatment
response suggests that IFNk may be an attractive alternative toJournal of Hepatology 2012IFNa. Indeed, IFNk has a limited effect on hematopoietic cells
and the central nervous system, promising antiviral activity in
the liver and limited receptor expression.
Zymogenetics and Bristol-Myers Squibb have developed Peg-
IFNk1 and are assessing its efﬁcacy in the treatment of HCV. A
phase 1b study was published in 2010 [129].
The phase IIb study reported a higher early virological
response (EVR) following treatment with PegIFNk combined with
RBV than with PegIFNa, in patients with genotype 1 and 4. Inter-
estingly, at different weekly doses of PegIFNk (240 to 120 lg),
cEVR rates were 55–56.3% compared to 37.9% with 180 lg of
PegIFNa in genotype 1 and 4 patients. The tolerability and safety
of PegIFNk were better than with PegIFNa, with less anemia and
fewer ﬂu-like symptoms [130]. These ﬁndings show that PegIFNk
has an antiviral effect against HCV. However, further and longer
studies on the effect of PegIFNk are needed. Interestingly,
rs12979860 CC was associated with an increase in SVR in patients
treated with PegIFN (Fig. 2).
IL-28B and triple therapies
In naïve and previously treated genotype 1 patients, the present
standard of care is triple therapy with the protease inhibitor boce-
previr or telaprevir combined with PegIFN and RBV [131–134]. IL-
28B status and response to therapy have been evaluated for tela-
previr and boceprevir used in combination with PegIFNa/RBV. In
studies of boceprevir triple therapy in both naïve and experienced
genotype 1 patients, IL-28B CC genotype was associated with a
higher SVR rate [131,134]. Moreover, the favorable genotype
was signiﬁcantly associated with undetectable HCV RNA after
8 weeks of therapy in both naïve (89% for CC vs. 52% for CT and
TT) and experienced patients (89–82% for the CC genotype vs.
52% and 51% for CT and TT) [131,134]. Therefore, IL-28B may be
used to identify patients who are eligible for shorter therapy. In
naïve genotype 1 patients treated with boceprevir, the IL-28B
polymorphism was an independent predictor of SVR. SVR rates
were higher in CC, CT, and TT patients receiving triple therapy.
The differences in SVR rates in patients receiving either PegIFN/
RBV or triple therapy were more marked in CT and TT patients
than in CC patients (40% and 30% in CT and TT vs. 3% in CC).vol. 57 j 1110–1125 1119
Box 5
IFNs lambda: signaling and activity
IFN type III or IFNλ
and type III IFN induce the same signal transduction and share identical biological activities. IFNsλ belongs to a cytokine type 2 family 
including IL-10, IL-22 and IL-26. There are three IFNsλ encoded by three genes clustered on human Chr19, IFNλ1 (IL-29), IFNλ2 
(IL-28A) and IFNλ3 (IL-28B). 
IFNsλ expression is induced by LPS or double stranded RNA TLR stimulation [150]. Plasmacytoid dendritic cells are the main producers 
of IFNsλ. Types I and III IFNs are co-produced in response to the same inducers suggesting a common mechanism of regulation. IFNsλ 
 and IL-10R2 shared among the cytokine 
2 family members. While IL-10R2 is ubiquitously expressed, IFNLR1 expression is limited to certain type of cells. A high level of 
expression of IFNLR1 has been reported in hepatocytes from liver biopsies [151, 152].
IFNsλ stimulation results in the activation of IFN-stimulated gene expression (ISGs). IFNsλ and type I IFNs binding to their receptors 
activates the protein kinases Jak1 and Tyk2, leading to activation of downstream STATs. Activated STAT1 and STAT2 heterodimerize with 
IRF9 and form the ISGF3 complex. The activated complex translocates into the nucleus to activate ISGs transcription by recognition of 
their IFN-stimulated response element (IRSE) within the promoter region [153, 154]. Moreover, all class II cytokines including IFNsλ are 
able to activate STAT1 ad STAT3. The heterodimer STAT1/STAT3 then translocates into the nucleus and binds IFNλ-activated sites 
(GAS) again resulting in ISGs transcription [155]. Hundreds of ISGs are produced in response to IFNs stimulation. Evidence has shown 
that even if different IFNs signal through the same pathway each IFN can induce the activation of different ISGs [156, 157]. In the 
HCV replicon system, Marcello et al. reported that while IFNλ induced a steady increase in ISGs levels, type I IFNs peaked early and 
declined rapidly [101]. These results supported a distinct antiviral state of type I and III IFNs. 
The effect of type III IFNs on immune cell function is not fully understood. It has been reported that IFNλ decreases the production of 
Th2-type cytokines, potentially activating a Th1 immune pathway [158-161].
  
In vitro, the antiviral activity of IFNsλ has been described for several viruses including HCV and HBV [101, 153, 162]. Recently, Zhang 
et al. showed that IL-28B signal through the Jak/STAT pathway in HCV replicating cells [163].
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ReviewTelaprevir-based therapy improved both RVR and SVR across
all different rs12979860 genotypes (Fig. 2) [135]. Although only
Caucasians were genotyped for IL-28B SNP, there was an increase1120 Journal of Hepatology 2012in SVR rates across all IL-28B genotypes in genotype 1 naïve
patients treated with telaprevir triple therapy. Patients with the
CC genotype were most likely to achieve an RVR and to havevol. 57 j 1110–1125
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shorter treatment duration. The difference in SVR rates between
patients receiving triple therapy and PegIFN/RBV was more
marked in patients with the T allele than in those with the CC
genotype [135]. There was no signiﬁcant difference in SVR rates
across the different IL-28B genotypes with telaprevir triple ther-
apy in genotype 1 experienced patients [136].
Multivariate analysis identiﬁed rs8099917 genotype TT and
substitution at aa 70 (Arg70) as signiﬁcant determinants of SVR
after a 12-week or 24-week regimen of triple therapy in patients
with HCV genotype 1 [118]. The efﬁcacy of triple therapywas high
in patients with the favorable genotype with an SVR rate of 84%,
whatever substitution of core aa 70. However, in patients with
the unfavorable genotype, the presence of Arg or Gly at position
70 in the core region was associated with a 50% and 12% SVR
respectively [118].
The INFORM-1 study reported that a dual combination of the
nucleoside polymerase inhibitor mericitabine and the HCV prote-
ase inhibitor danoprevir produced a rapid and substantial
decrease in viral load that was maintained throughout two weeks
of treatment [137]. Finally, themean reduction in HCV RNA serum
levels with the IFN-free regimen was slightly higher in patients
with CC polymorphism than in those with CT and TT [138].
Overall, the ability to predict the SVR in patients receiving tri-
ple therapy has not been fully evaluated. IL-28Bmay have limited
predictive value in patients with prior failure to PegIFN/RBV.
Moreover, in patients with the favorable IL-28B genotype, it
may be difﬁcult to not use triple therapy considering the overall
increase SVR rates, reported in the different trials, and the possi-
bility of a shorten treatment duration.
For genotype 4, the current treatment remains the combina-
tion of PegIFN/RBV, thus the IL-28B polymorphism may be an
important factor associated with response. Further studies are
needed to determine whether patients with genotype 4 and good
predictors of response, including IL-28B CC, can beneﬁt from
shorter therapy.Conclusions
Prediction of both progression of ﬁbrosis and SVR are main issues
in chronic hepatitis C. Major advances in genetics during the last
decade, allow the identiﬁcation of speciﬁc markers associated
with either ﬁbrosis progression or viral response. In particular,
SNPs located within genes encoding MMP-1 and MMP-9, MCP1,
PNLPA3, and vitamin D receptor have been associated with rapid
progression of ﬁbrosis. Moreover, CRS comprising 7 different
SNPs was able to discriminate patients with high risk of
developing a rapid ﬁbrosis progression from those who will
remain at low stages of ﬁbrosis. Since the description of IL-28B
SNPs association with both natural and treatment-induced HCV
clearance, many studies have investigated the use of these factors
for the prediction of viral response. IL-28B has been strongly
associated with viral response in all reports, including large
cohorts of patients.
However, for the single patient, the use of IL-28B as a predic-
tive factor of treatment outcome and decision to treat is not suf-
ﬁcient. IL-28B should probably be combined with other markers
to increase baseline prediction of treatment outcome.
During treatment, RVR is the strongest predictor of SVR even
compared to IL28 SNPs. For individual patients, RVR may repre-
sent global predictors (host and viral) for response. Interestingly,
the rs12979860 CC genotype was highly associated with viralJournal of Hepatology 2012response in patients who did not achieve an RVR [121]. Recent
studies have suggested that in triple therapy IL-28B genotyping
identiﬁes patients who might be eligible for shorter therapy
[135,139]. In genotype 1 experienced patients, previous response
(relapse, partial response, non-response) appears to be a stronger
predictor than IL-28B status. If strong predictive factors of treat-
ment response are identiﬁed for triple therapy for HCV-G1, the
duration of treatment may be shortened.Conﬂict of interest
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